New Dual Therapy PBS Restrictions for Pulmonary Arterial Hypertension (PAH) Medicines
Page last updated: 1 October 2020
Access to PAH medicines has improved as an outcome of the Post-market Review of PAH medicines. Effective 1 October 2020, PAH patients with World Health Organisation (WHO) Functional Class (FC) III or IV symptoms will have access to endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE-5i) medicines for dual therapy. Refer to the fact sheet for further details on these changes.
